Total
0
Shares
Zelira Therapeutics (ASX:ZLD) - CEO, Dr Oludare Odumosu - The Market Herald
CEO, Dr Oludare Odumosu
Source: Gene Smirnov
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Zelira Therapeutics (ZLD) signs a five-year distribution with Health House International to launch its SprinjeneCBD toothpaste in the UK
  • The toothpaste is made up of zinc and black seed oil which are known to fight conditions like gingivitis and reduce gum inflammation
  • To keep exclusivity, Health House is required to purchase US$250,000 (around A$324,555) of the toothpaste in the first six months
  • The agreement can be terminated mutually or when one party fails to perform by giving 180 days written notice
  • Zelira is up 2.13 per cent and shares are trading at 4.8 cents at 1:03 pm AEST

Zelira Therapeutics (ZLD) has signed a five-year distribution with Health House International (HHI) to launch CBD toothpaste in the UK.

The company's SprinjeneCBD toothpaste brand is now available in the United States and the United Kingdom.

"The Zelira CBD toothpaste brand manufactured by Sprinjene in the US. represents a unique product offering in Oral Healthcare, which adds to Health House's existing range of cannabis products," Health House Chief Operating Officer Tony Samios said.

"It is made up of patented formulation of zinc, black seed oil and CBD which are thought to fight conditions like gingivitis and reduce gum inflammation, and to which the addition of CBD could make this even more effective."

To keep exclusivity, Health House is required to purchase US$250,000 (around A$324,555) of the toothpaste in the first six months and US$500,000 (around A$649,110) in the first 12 months.

Furthermore, the agreement can be terminated mutually or when one party fails to perform by giving 180 days written notice.

"Zelira took a very strategic position in the cannabinoid-based consumer product segment with the successful launch of our first SprinjeneCBD oral care toothpaste product in the US," Zelira Managing Director Dr Oludare Odumosu commented.

"Health House International has established distribution networks in emerging markets such as the UK, and will be a key channel as we continue to grow our global distribution footprint."

Zelira was up 2.13 per cent on the market with shares trading at 4.8 cents at 1:03 pm AEST.

ZLD by the numbers
More From The Market Herald
BARD1 Life Sciences (ASX:BD1) - CEO, Leearne Hinch - The Market Herald

" BARD1 Life Sciences (ASX:BD1) updates the market on Q4

BARD1 Life Sciences (BD1) has reported advances across its sales, business development and commercialisation activities over the June quarter.
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) has a progressive fourth quarter

Incannex Healthcare (IHL) has spent the fourth quarter progressing its cannabinoid pharmaceutical products and psychedelic medicine therapies.
Prescient Therapeutics (PTX) - CEO & Managing Director, Steven Yatomi Clarke - The Market Herald

" Prescient Therapeutics (ASX:PTX) advances clinical studies in June quarter

Prescient Therapeutics (PTX) has summarised its operations and cashflow for the June quarter.
Mesoblast (ASX:MSB) - Managing Director & CEO, Silviu Itescu - The Market Herald

" Mesoblast (ASX:MSB) trades lower following June quarterly report

Drug developer Mesoblast (MSB) is trading red following the release of its latest quarterly financial report.